178 related articles for article (PubMed ID: 11004527)
41. Xaa-Pro-dipeptidyl-aminopeptidase from Lactococcus lactis catalyses kinetically controlled synthesis of peptide bonds involving proline.
Yoshpe-Besançon I; Gripon JC; Ribadeau-Dumas B
Biotechnol Appl Biochem; 1994 Aug; 20(1):131-40. PubMed ID: 7917062
[TBL] [Abstract][Full Text] [Related]
42. A study to evaluate the potential of an in silico approach for predicting dipeptidyl peptidase-IV inhibitory activity in vitro of protein hydrolysates.
Wang TY; Hsieh CH; Hung CC; Jao CL; Lin PY; Hsieh YL; Hsu KC
Food Chem; 2017 Nov; 234():431-438. PubMed ID: 28551257
[TBL] [Abstract][Full Text] [Related]
43. New results on the conformations of potent DP IV (CD26) inhibitors bearing the N-terminal MWP structural motif.
Mrestani-Klaus C; Brandt W; Faust J; Wrenger S; Reinhold D; Ansorge S; Neubert K
Adv Exp Med Biol; 2003; 524():65-8. PubMed ID: 12675224
[No Abstract] [Full Text] [Related]
44. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII.
Leiting B; Pryor KD; Wu JK; Marsilio F; Patel RA; Craik CS; Ellman JA; Cummings RT; Thornberry NA
Biochem J; 2003 Apr; 371(Pt 2):525-32. PubMed ID: 12529175
[TBL] [Abstract][Full Text] [Related]
45. Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY.
Unniappan S; McIntosh CH; Demuth HU; Heiser U; Wolf R; Kieffer TJ
Diabetologia; 2006 Aug; 49(8):1915-23. PubMed ID: 16802131
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory action of proline-containing peptides on Xaa-Pro-dipeptidylaminopeptidase.
Harada M; Fukasawa KM; Fukasawa K; Nagatsu T
Biochim Biophys Acta; 1982 Jul; 705(2):288-90. PubMed ID: 6126216
[No Abstract] [Full Text] [Related]
47. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.
Rosenblum JS; Kozarich JW
Curr Opin Chem Biol; 2003 Aug; 7(4):496-504. PubMed ID: 12941425
[TBL] [Abstract][Full Text] [Related]
48. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.
Pospisilik JA; Stafford SG; Demuth HU; Brownsey R; Parkhouse W; Finegood DT; McIntosh CH; Pederson RA
Diabetes; 2002 Apr; 51(4):943-50. PubMed ID: 11916911
[TBL] [Abstract][Full Text] [Related]
49. The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells.
Wrenger S; Reinhold D; Hoffmann T; Kraft M; Frank R; Faust J; Neubert K; Ansorge S
FEBS Lett; 1996 Apr; 383(3):145-9. PubMed ID: 8925885
[TBL] [Abstract][Full Text] [Related]
50. The conformation around the peptide bond between the P1- and P2-positions is important for catalytic activity of some proline-specific proteases.
Fischer G; Heins J; Barth A
Biochim Biophys Acta; 1983 Feb; 742(3):452-62. PubMed ID: 6340741
[TBL] [Abstract][Full Text] [Related]
51. Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions.
Biton A; Ansorge S; Bank U; Täger M; Reinhold D; Brocke S
Immunobiology; 2011 Dec; 216(12):1295-301. PubMed ID: 21802166
[TBL] [Abstract][Full Text] [Related]
52. Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones.
Reinhold D; Hemmer B; Gran B; Born I; Faust J; Neubert K; McFarland HF; Martin R; Ansorge S
J Neuroimmunol; 1998 Jul; 87(1-2):203-9. PubMed ID: 9670864
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary electrophoresis.
Hoffmann T; Reinhold D; Kähne T; Faust J; Neubert K; Frank R; Ansorge S
J Chromatogr A; 1995 Nov; 716(1-2):355-62. PubMed ID: 8574390
[TBL] [Abstract][Full Text] [Related]
54. Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors.
Ashton WT; Dong H; Sisco RM; Doss GA; Leiting B; Patel RA; Wu JK; Marsilio F; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2004 Feb; 14(4):859-63. PubMed ID: 15012982
[TBL] [Abstract][Full Text] [Related]
55. Side-chain effects on peptidyl-prolyl cis/trans isomerisation.
Reimer U; Scherer G; Drewello M; Kruber S; Schutkowski M; Fischer G
J Mol Biol; 1998 Jun; 279(2):449-60. PubMed ID: 9642049
[TBL] [Abstract][Full Text] [Related]
56. Proline-dependent structural and biological properties of peptides and proteins.
Yaron A; Naider F
Crit Rev Biochem Mol Biol; 1993; 28(1):31-81. PubMed ID: 8444042
[TBL] [Abstract][Full Text] [Related]
57. AoS28D, a proline-Xaa carboxypeptidase secreted by Aspergillus oryzae.
Salamin K; Eugster PJ; Jousson O; Waridel P; Grouzmann E; Monod M
Appl Microbiol Biotechnol; 2017 May; 101(10):4129-4137. PubMed ID: 28229206
[TBL] [Abstract][Full Text] [Related]
58. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV.
Tanaka S; Murakami T; Horikawa H; Sugiura M; Kawashima K; Sugita T
Int J Immunopharmacol; 1997 Jan; 19(1):15-24. PubMed ID: 9226475
[TBL] [Abstract][Full Text] [Related]
59. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.
Reinhold D; Biton A; Pieper S; Lendeckel U; Faust J; Neubert K; Bank U; Täger M; Ansorge S; Brocke S
Int Immunopharmacol; 2006 Dec; 6(13-14):1935-42. PubMed ID: 17161346
[TBL] [Abstract][Full Text] [Related]
60. Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition.
Gutheil WG; Bachovchin WW
Biochemistry; 1993 Aug; 32(34):8723-31. PubMed ID: 8103356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
